DEFA14A: Recursion to Acquire Exscientia in Landmark Deal, Creating AI-Powered Drug Discovery Giant

Recursion Pharmaceuticals will acquire Exscientia in a stock-based transaction, aiming to combine their AI-driven drug discovery platforms and pipelines.

Summary

• Recursion Pharmaceuticals and Exscientia have entered into a definitive agreement for Recursion to acquire Exscientia.
• Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share.
• Recursion shareholders are expected to own approximately 74% and Exscientia shareholders approximately 26% of the combined company.
• The combined company will have approximately $850 million in cash and cash equivalents as of the end of Q2 2024.
• Annual synergies are estimated at approximately $100 million, extending the cash runway into 2027.
• The transaction is expected to close by early 2025, pending customary approvals.
• The combined company will be named Recursion and will be headquartered in Salt Lake City, Utah.
• Chris Gibson will serve as CEO, and David Hallett plans to join as Chief Scientific Officer.
• The combined company expects approximately 10 clinical trial readouts in the next 18 months.
• The combined company has potential for approximately $200 million in milestone payments over the next 2 years from current partnerships.
• The combined company has potential for over $20 billion in revenue before royalties over the course of the partnerships.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the strategic combination, potential synergies, and promising pipeline. The forward-looking statements and management's enthusiasm contribute to the positive sentiment.

Positives

• The combined company will have a diverse pipeline with approximately 10 clinical readouts expected in the next 18 months.
• The combined company has potential for approximately $200 million in milestone payments over the next 2 years from current partnerships.
• The combined company has potential for over $20 billion in revenue before royalties over the course of the partnerships.
• The combined company will have approximately $850 million in cash and cash equivalents as of the end of Q2 2024.
• Annual synergies are estimated at approximately $100 million, extending the cash runway into 2027.
• The combination is expected to create a full-stack technology-enabled small molecule discovery platform.
• The combined company will have a strong leadership team with Chris Gibson as CEO and David Hallett as Chief Scientific Officer.

Risks

• The transaction is subject to customary closing conditions, including shareholder and regulatory approvals.
• The integration of Exscientias business with Recursions business may be challenging.
• The combined company may not be able to realize the expected synergies.
• The combined company may face competition from other drug discovery companies.
• The combined company may be affected by changes in economic, market, or business conditions.

Future Outlook

The combined company expects to read out approximately 10 clinical trials in the next 18 months and aims to deliver better treatments to patients faster and at a lower cost.

Management Comments

• Chris Gibson stated that the combination is deeply complementary and aligned with their missions to industrialize drug discovery.
• David Hallett expressed excitement about bringing the teams together to accelerate the discovery of better drugs for patients.

Industry Context

The announcement reflects a growing trend in the pharmaceutical industry towards leveraging AI and technology to improve drug discovery and development efficiency.

Comparison to Industry Standards

• The combined company aims to create a full-stack technology-enabled small molecule discovery platform, similar to efforts by companies like Schrödinger and Relay Therapeutics.
• The focus on AI-driven drug discovery aligns with the strategies of companies like Atomwise and Insitro.
• The partnership approach mirrors collaborations seen between traditional pharmaceutical companies and AI-focused drug discovery firms, such as the partnership between Amgen and Generate Biomedicines.
• The goal of achieving annual peak sales opportunities in excess of $1 billion for successful programs is a common benchmark in the pharmaceutical industry, comparable to targets set by companies like Vertex Pharmaceuticals and Regeneron.

Management Changes

Stakeholder Impact

• Shareholders of both companies will be impacted by the stock-based transaction and the potential for future growth and synergies.
• Employees of both companies may experience changes in roles and responsibilities as the companies integrate.
• Customers and partners of both companies can expect a broader range of services and capabilities from the combined entity.
• Suppliers and creditors may be affected by the financial performance and stability of the combined company.

Next Steps

• Obtain Recursions stockholder approval.
• Obtain Exscientias shareholder approval.
• Obtain the sanction of the High Court of Justice of England and Wales.
• Receive required regulatory approvals.
• Close the transaction, expected by early 2025.

Key Dates

Keywords

Acquisition, Recursion, Exscientia, Drug discovery, AI, Partnerships, Clinical trials, Milestone payments, Synergies, Pharmaceuticals